LEGN
Legend Biotech Corporation American Depositary Shares
Pharmaceutical Preparations
Best Pharmaceutical Stocks 2026 →
Legend Biotech (LEGN) Stock: Buy, Sell, or Hold?
$19.54
-0.87 (-4.26%)
▼
5d:
-14.19%
30d:
+9.28%
90d:
-3.6%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (45%)
Quality Score
33/100
Position
FAIR
30-Day Fair Range
$18.40 – $21.99
Position: FAIR
Forward P/E & Valuation
28.7x
CHEAP
vs 32.0x historical avg
Wall Street Target
$44.01
+125.2% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$18.87 / $24.42
Trend: Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
⏸️ WAIT FOR STABILIZATION: LEGN is down 14.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Get Alerted When LEGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$23.89
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$14.84
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: LEGN is currently trading at $19.54, which is considered fair relative to its 30-day fair value range of $18.40 to $21.99. From a valuation perspective, the stock is trading at a discount (Forward PE: 28.6) compared to its historical average (32.0). Remarkably, the market is currently pricing in an annual earnings decline of 3.6% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, LEGN is in a downtrend. Immediate support is located at $18.87, while resistance sits at $24.42. Short-term momentum is weak, with the stock down 4.3% recently.
Market Sentiment: LEGN scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $44.01 (+125.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, LEGN is in a downtrend. Immediate support is located at $18.87, while resistance sits at $24.42. Short-term momentum is weak, with the stock down 4.3% recently.
Market Sentiment: LEGN scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $44.01 (+125.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$18.40 -
$21.99
Company Quality Score
33/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
45.2%
Trading Range & Key Levels
30-Day Trading Range
$18.40 -
$21.99
Current vs Trading Range
FAIR
Support Level
$18.87
Resistance Level
$24.42
Current Trend
Downtrend
Technical data as of
Nov 11, 2026
Quantitative Signal Breakdown
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (20/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.3%)
- BULLISH: Trading 125.2% below Wall St target ($44.01)
- WARNING: Composite score 33/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
28.65
Wall Street Target
$44.01
(+125.2%)
Revenue Growth (YoY)
51.9%
Profit Margin
-7.2%
Valuation Discount vs History
-3.6% cheaper
PE vs Historical
28.7 vs 32.0
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.6%
(market-implied from PE analysis)
1-Year Target
$18.84
(-4%)
2-Year Target
$18.16
(-7%)
3-Year Target
$17.50
(-10%)
3-Yr Target (if PE normalizes)
(PE: 29→32)
$19.55
(+0%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 28.6 to 32.0
Stabilization Target:
$21.83
(+11.7%)
PE Expansion Potential:
+11.7%
Share LEGN Analysis
Share this live LEGN analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (LEGN)
Bearish
1 Retail Mentions
Reddit / WSB Comments
1
Bearish
Last Tracked
Jun 2, 2026
Daily AI digest
AI Retail Discussion Summary:
Reddit & WallStreetBets discussions on LEGN are bearish (sentiment score +0.00) across 1 tracked comments.
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 7:24 AM ET
Data refreshes hourly during market hours. Next update: 8:24 AM
Data refreshes hourly during market hours. Next update: 8:24 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LEGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
REGN
Regeneron Pharmaceutical… |
BUY
28 analysts |
$978 | 35 SELL |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$145 | 31 SELL |
|
ARGX
argenx NV ADR |
STRONG BUY
23 analysts |
$1147 | 35 SELL |
|
BNTX
BioNTech SE |
BUY
21 analysts |
$114 | 62 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
22 analysts |
$296 | 31 SELL |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive LEGN Research Pages
